UTv Videos

Murphy shares the backstory of how PSMA PET/CT imaging has emerged as a major advancement in the prostate cancer armamentarium.

Gomella looks back on the year's top headlines in bladder cancer, from FDA approvals to notable clinical trial results.

“Some women described not being told any risks of the surgery… while other women did recall having risks described,” says investigator Pansy Uberoi, MD, MPH.

Urology residency program applicants continue to face interview questions on restricted topics such as plans for having children.

Investigators observed a median 74% reduction in urinary incontinence episodes at 1 year for women undergoing group-based pelvic floor muscle training compared with a 70% reduction in women undergoing individual PFMT.

Christopher P. Evans, MD, discusses his active surveillance protocol with J. Brantley Thrasher, MD.

Samuel J. Peretsman, MD, explains how he incorporated HIFU into his practice.

Anne M. Suskind, MD, MS, discusses the findings of the recent study, published in Urology.

Meena Davuluri, MD, MPH, and Kara L. Watts, MD, discuss findings from a study published in Urology Practice.

Amanda North, MD, outlines finding from a paper recently published in Urology Practice.

In this interview, Gopal H. Badlani speaks to Jeffrey P. Weiss, MD, regarding how Weiss defines nocturia and separating the symptom from overactive bladder.

In this video, Eric Klein, MD, discusses a study evaluating the 17-gene Oncotype DX Genomic Prostate Score assay in African American and Caucasian American men.

Urology Times® Editorial Council Member Priya Padmanabhan, MD, MPH, professor of urology at Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, discusses how she has been affected by the coronavirus disease 2019 (COVID-19) pandemic.

Kevin McVary, MD, of Loyola University Medical Center in Maywood, IL, provides urologists with tips on how to assess the adoptability of minimally invasive surgical therapies for BPH.

In this video, Scott Eggener, MD, outlines which patients are the best candidates for focal therapy for prostate cancer, and discusses the differences in follow-up for patients treated with focal therapy compared with those undergoing active surveillance.

Martin Gleave, MD, of the University of British Columbia in Vancouver, discusses the Genomic Umbrella Neoadjuvant Study (GUNS) trial, which uses a multi-arm, multistage adaptive design to test targeted therapies in patients with high-risk localized disease by matching neoadjuvant therapies to baseline genomic alterations.

LUGPA President Dr. Harris discusses legislative/policy challenges in 2020.